Raymond James analyst Joseph Altobello maintained a Market Perform rating on the stock.
Raymond James attributed bottom-line strength to price increases and cost savings initiatives, which, coupled with supply chain investments, drove a gross-margin inflection.
“Here, the benefits of pricing (+220 bps) and cost savings (+140 bps) more than offset higher manufacturing and logistics costs (-190 bps) and commodity costs (-120 bps),” Altobello wrote in a note, noting additional aid from a lower-than-expected tax rate.
Clorox plans to continue improving price competitiveness and targets Burt’s Bees for the next round of raises.
Raymond James doesn't expect the strategy to impact revenue, which recently swelled on volume improvement amid forex headwinds.
“However, management kept its fiscal 2019 outlook unchanged given the timing of supply chain investment, greater FX headwinds, as well as a likely increase in trade promotion spending for Glad,” Altobello wrote. “Thus, we continue to believe the stock’s valuation fairly reflects the company’s solid overall execution amid this challenging environment.”
At time of publication, Clorox shares traded lower by 2.8 percent at $153.81.
A Few Key Takeaways From Clorox's Analyst Presentation
Pro: Consumer Goods Stocks Surging In 'Clear Change' In Market Leadership
Latest Ratings for CLX
|Dec 2018||Wells Fargo||Maintains||Market Perform||Market Perform|
View More Analyst Ratings for CLX
View the Latest Analyst Ratings
See more from Benzinga
- AMD Falls As Major Shareholder Sells
- January Auto Sales Freeze Amid Poor Weather, Federal Shutdown
- Raymond James: Charter's Fee Cash Flow Will Rise On Declining Capex
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.